Oncology Research is committed to publishing high-quality, innovative research that is focused on the entire range of preclinical, translational, and clinical cancer therapeutics. Specific areas of interest include preclinical and translational research in development of novel small molecules and targeted therapies; mechanisms of drug sensitivity; mechanisms of cellular drug resistance; biomarkers of response and/or resistance; novel experimental model systems and technologies relating to cancer therapeutics;pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy and clinical immunology; gene therapy; and radiobiology and novel approaches to radiation therapy either alone or in combination with chemotherapy. For studies that investigate the role of microRNAs and non-coding RNAs as regulators of cellular gene expression, it will be important for more in-depth mechanistic studies to be conducted that confirm their biological activity and their potential effect as mediators of chemosensitivity. As part of the preclinical cancer therapeutics focus, the journal also prioritizes preclinical studies that are focused on drug design, chemical biology, and drug screening. While the journal’s primary focus is on small molecules and protein drugs, other molecular entities may be considered. In addition, submissions that investigate the potential role of herbal/botanical medicines in preclinical and clinical cancer therapy are welcomed; however, it will be important to document that these medicines are of high quality, with confirmation of batch to batch consistency. In addition to original peer-reviewed articles, the journal also welcomes timely reviews and/or commentaries on topics that focus on preclinical, translational, and/or clinical cancer therapeutics
American Continent: Edward Chu University of Pittsburgh Cancer Institute, USA Email: firstname.lastname@example.org
American Continent: Edward Chu, Co-Editor-in-Chief L. J. Appleman, University of Pittsburgh, USA N. Bahary, University of Pittsburgh, USA J. R. Bertino, Rutgers Cancer Institute of New Jersey, USA J. H. Beumer, Hillman Cancer Center, USA M. Boyiadzis, University of Pittsburgh, USA Y.-C. Cheng, Yale University School of Medicine, USA M. S. Copur, University of Nebraska, USA A. Krishnamurthy, University of Pittsburgh, ISA J. J. Lee, University of Pittsburgh, USA Y. Li, Sanford Burnham Prebys Medical Discovery Institute, USA G. D. Roodman, Indiana University, USA M. Rudek, Johns Hopkins University, USA J. C. Schmitz, University of Pittsburgh, USA L. Zhang, University of Pittsburgh, USA European Continent: Enrico Mini, Co-Editor-in-Chief A. H. Calvert, University of Newcastle upon Tyne, UK A. Di Paolo, University of Pisa, Italy P. Workman, CRC Center for Cancer Therapeutics, UK Asia and Pacific Rim: Kazuo Umezawa, Co-Editor-in-Chief A. Deguchi, Tokyo Women’s Medical University, Japan S. Gantsev, Bashkirian State Medical University, Russia R. Horie, Kitasato University, Japan Y. Horiguchi, Tokyo Medical University, Japan M. Imoto, Keio University, Japan H. Kakeya, Kyoto University, Japan M. Kawatani, RIKEN, Japan E. Kikuchi, Keio University, Japan N. Koide, Aichi Medical University, Japan Y. Lin, Aichi Medical University, Japan J. Neuzil, Griffith University, Gold Coast Campus, Australia O. Ohno, Keio University, Japan T. Ohsugi, Rakuno Gakuen University, Japan H. Osada, RIKEN, Japan M. Oya, Keio University, Japan M. Ozaki, Hokkaido University, Japan Y. Sasazawa, Keio University, Japan K. Sidthipong, Mahidol University, Thailand S. Simizu, Keio University, Japan M. Takeiri, Kyoto University, Japan E. Tashiro, Keio University, Japan T. Ueno, Kyoto University Hospital, Japan M. Yamamoto, Waseda University, Japan
INSTRUCTIONS TO CONTRIBUTORS
Open Access: Oncology Research is an open access journal and follows rules governed by open access publications. Accepted refereed articles published in the journal will be placed on the internet and will be publicly accessible, free of charge. In order to cover the costs of the journal, authors are expected to pay a publication fee. A $50.00 nonrefundable submission fee is required when your manuscript is sent out for review. You will also be asked to confirm that, if your manuscript is accepted for publication, you will pay the relatively inexpensive open access fee of $600.00 for less than 5 pages, or $1,000.00 for 5–12 pages and $50.00 for each additional page over 12 when billed at proof stage. The Open Access fee entitles the corresponding author to a free PDF file of the final version in addition to a hard copy of the journal issue. Color Options: Your article may contain figures that should be printed in color. There is a charge for figures appearing in color. The cost is $450.00 for figures appearing in color (this fee is for unlimited figures in one article).
Types of Contributions: The Journal publishes full-length papers and short communications, in English, describing the results of original experiments in basic and clinical cancer research. Commentaries, short research editorials of between 3,000 and 5,000 wordsin length (12–20 typewritten pages, double-spaced) are also published. These are editorial statements intended to stimulate thought on selected topics and should not be exhaustive reviews. They can be controversial and can focus on areas subject to muchactivity, or draw attention to relatively neglected fields in which there are both opportunities and the need for research. Authors may present personal views on the state of the subject on which they are reporting, and give their view as to where in the nearor distant future the subject may be moving. Authors are encouraged to take issue with popular dogmas. Manuscripts are published in the shortest time possible commensurate with scientific quality.
Submission Requirements: Authors should submit the original manuscript electronically via email to email@example.com. Send the text portion of the manuscript, including tables and figure legends, as an email attachment in Microsoft Word (IBMcompatible) format. Send the figures as separate files (Microsoft Word, or as tiff or jpeg). Note that large graphic files, especially color, may need to be compressed (zipped) to send via email.
Include a cover letter, and insert “Oncology Research Submission” in the subject line of the email. The cover letter should contain the name, address, telephone, and fax number and electronic mail address of the author responsible for correspondence. Followthe General Manuscript Form guidelines below to prepare the manuscript, figures, and tables.
Manuscripts are accepted for consideration with the understanding that they have not been published elsewhere except in abstract form and are not concurrently under review elsewhere. Material accepted for publication will not be released publicly priorto its appearance in the journal. Authors are notified by the appropriate editorial office if the manuscript is accepted for publication.
General Manuscript Form: Manuscripts should be typed in English, double spaced throughout with at least 3-cm margins. Please consult the most recent issue of the journal for style and format. Number all pages consecutively, beginning with the title page.Use metric units of measure; other units may be given in parentheses. Typically, only three levels of headings are recognized. The manuscript should be organized as follows.
Title Page: The title should be brief and specific. The title page should contain in the following order: title, name(s) and affiliation(s) of author(s) including department institution, city, state, and country, and a suggested short title for the running head ofnot more than 50 characters and spaces. Also indicate the author to whom correspondence should be addressed and provide complete mailing address, telephone and fax numbers (optional), and e-mail address.
Abstract/Key Words: An abstract of 300 words or less should begin on page 2. It should contain a concise summary of the results, conclusions, and other significant points. For the purpose of subject indexing, provide four to six key words immediately followingthe abstract.
Text: Arrange the text with main headings of Introduction, Materials and Methods, Results, Discussion, Acknowledgments (and source of funding), References, Tables, Figure legends (together, and separate from the figures), and Figures (or as separatefiles). Use generic names of drugs. Give name, city and state, and country of the manufacturer of any chemicals, equipment, or software mentioned in the text. Define all nonstandard abbreviations the first time they appear in the text.
References: Literature cited should be prepared according to the Council of Science Editors format (citation-sequence system). This format is conveniently in Endnote and the output style is available at the following site: http://endnote.com/downloads/style/cse-style-manual-7th-ed-citation-sequence. Some examples are provided below. References in the text should be cited by superscript number separated by a comma and listed in numerical order as they appear in the text (double spaced) on a separate page at the end of the manuscript. Journal citations in the reference list should contain the following: (a) reference number (note NOT superscript); (b) surnames and initials of all authors (surnames precede initials); (c) title of article; (d) journal title abbreviated as listed in ISSN.org; (e) year; volume, inclusive pages. See the examples shown and refer to Council of Science Editors format for more examples.
Journal Article: 1. Roth CG, Gillespie-Twardy A, Marks S. Agha M, Raptis A, Hou JZ, Farah R, Lin Y, Qian Y, Pantanowitz L, Boyiadzis M. Flow cytometric evaluation of double/triple hit lymphoma. Oncol Res. 2016;23(3):137-46. Book: 1. Weinberg RA. The biology of cancer, 2nd ed. New York (NY): Garland Science; 2014. Book Article/Chapter: 1. Hasskarl J. Sorafenib: Targeting multiple tyrosine kinases in cancer. In: Martens UM, editor. Small molecules in oncology, 2nd ed. Berlin, Germany: Springer-Verlag; 2014. p. 145-164. Internet Source: 1. Cancer of the Colon and Rectum – SEER Stat Fact Sheets. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2011). Rockville (MD): National Cancer Institute; 2014 [accessed 2014 June 30]. http://seer.cancer.gov/statfacts/html/colorect.html
An example of an in-text citation is shown below.
Ovarian cancer is the third most common gynecological malignancy worldwide1,2.
To cite multiple sources, all numbers associated with the reference being cited should be superscript, separated by a comma, with no spaces between them.
Supplementary Material: Please note that the journal does not host supplementary material. If you wish to include supplementary material, then you will need to provide a link to a permanent hosting site of this material within the manuscript.
Tables: Tables should be numbered and cited sequentially in the text. Prepare each table as a separate page at the end of the manuscript text, after the references. Avoid very wide or long tables that would not fit a printed page. Each table should have a title, andeach column in the table should have a brief heading. Define all abbreviations in the table footnote at the bottom of the table.
Figures: Figures should be numbered and cited sequentially in the text. Prepare figures to provide high quality suitable for reproduction. Avoid light lettering and shading that will not reproduce well. Figure dimensions and scaling should be suitable forreduction (if necessary) to fit column or page size. Care must be taken that letters and other symbols do not become so small that they are illegible when the figure is reduced. Complex formulas should be prepared as illustrations. After acceptance final figures should be provided in high resolution. Simple black and white figures (e.g., line graphs, bar graphs, etc.) should be 1200 dpi. Halftone and color figures (or combo figures) should be 600 dpi. Final figure files should be submitted as tiff, jpg, or eps format. Do not include the figure number as part of the figure file (e.g., do not label Figure 1, etc., as part of the figure). Do not provide color in a figure file unless the figure will be printed in color (note there is a cost for printing figures in color). (Do not embed figureswithin the manuscript text. Prepare as separate files or at the end of the manuscript, after tables and figure legends.) There is a cost to reproduce figures in color. The author is required to bear the costs for the publication of color figures (costs and colorauthorization form will be provided at proof stage).
Figure Legends: List all figure legends sequentially on one or more pages at the end of the manuscript text, after the references, and identify all symbols used in the figures. The figure legend should be as clear as possible and should fully describe the contents of the figure. (Do not include the figure legend as part of the figure.) If the figure is from a previously published article, indicate that permission has been obtained from the original publisher.
Permissions: If data from any other source is used in tables or figures it is the responsibility of the author(s) to obtain permission to reproduce such material. Provide proof that permission has been granted from the original publisher and indicate thesource.
Page Proofs/Offprints: All material accepted for publication is subject to copyediting. Authors will receive page proofs of articles before publication, along with an Open Access authorization form (with the final cost based on number of printed pages) and Color Figure authorization form (if there are potential color figures), which will need to be completed and returned before the article can be processed for publication. Only minor corrections are allowed at proof stage. Author can also request an offprint order form for ordering offprints or additional journal copies.
The publishers and editorial board of Oncology Research have adopted the publication ethics and malpractice statements of the Committee on Publication Ethics (COPE) https://publicationethics.org/core-practices. These guidelines highlight what is expected of authors and what they can expect from the reviewers and editorial board in return. They also provide details of how problems will be handled. Briefly:
Author Responsibilities: Authors listed on a manuscript must have made a significant contribution to the study and/or writing of the manuscript. During revisions, authors cannot be removed without their permission and that of the other authors. All authors must also agree to the addition of new authors. It is the responsibility of the corresponding author to ensure that this occurs.
Financial support and conflicts of interest for all authors must be declared. Further information on this can be obtained from the International Committee for Medical Journal Editors (http://www.icmje.org/).
The reported research must be novel and authentic and the authors should confirm that the same data has not been and is not going to be submitted to another journal (unless already rejected). Statements made in the introduction and discussion should be supported by appropriate references and sufficient experimental detail should be provided to allow for repetition of the study by another group. Plagiarism of the text/data will not be tolerated and could result in retraction of an accepted article. Any text or figures reproduced for another source require the permission of the original copyright holders (normally the publishers).
Any manipulation of figures should be equally applied and described in the text including pseudo-coloring and must not change the meaning of the figure.
When humans, animals or tissue derived from them have been used, then mention of the appropriate ethical approval must be included in the manuscript.
Reviewer Responsibilities: Reviewers are expected to not possess any conflicts of interest with the authors and research. They should review the science objectively and provide recommendations for improvements where necessary. When aware of relevant published work not being cited, the reviewers should recommend inclusion of these references. If the reviewer feels that they would be unable to repeat the study as described, then additional methodological details should be requested. Any unpublished information read by a reviewer should be treated as confidential.
Editorial Responsibilities: The section editors are expected to select an appropriate number of reviewers for the manuscript so that they can make an informed decision about whether to reject/accept a manuscript. Their decision must be based only on the paper’s importance, originality and clarity and whether it is suitable for the journal. They must not have a conflict of interest with the authors or work described. The anonymity of the reviewers must be maintained.
Should problems come to light after acceptance then the editors agree to promote the publication of corrections and/or retractions as deemed necessary.
NIH Public Access Policy: Cognizant Communication Corporation does not upload manuscripts on the authors’ behalf to PubMedCentral. The authors of NIH-funded manuscripts are granted permission to upload the final version of the manuscript themselves to PubMedCentral so that they remain in compliance with the NIH Public Access Policy. A PDF of the article is provided to the Corresponding Author for this purpose.
Authors have the opportunity to download their articles from open access files at: http://www.ingentaconnect.com/content/cog/or
Publishing Responsibilities: The publishers agree to ensure that to the best of their abilities, the information that they publish is genuine and ethically sound. If publishing ethics issues come to light, not limited to accusations of fraudulent data or plagiarism, during or after the publication process, they will be investigated by the editorial board including contact with the authors’ institutions if necessary, so that a decision on the appropriate corrections, clarifications or retractions can be made. The publishers agree to publish this as necessary so as to maintain the integrity of the academic record.
Mitotic Arrest-Deficient Protein 2B Overexpressed in Lung Cancer Promotes Proliferation, EMT, and Metastasis – 859 Hua Zhang, Xiuquan He, Wenfei Yu, Bingqing Yue, Ziting Yu, and Ying Qin
Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer – 871 Xinwen Wang, Fupeng Zhang, Xi Yang, Meiping Xue, Xiaoli Li, Yu Gao, and Likun Liu
MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1 – 879 Wei Wu, Linyan He, Yan Huang, Likun Hou, Wei Zhang, Liping Zhang, and Chunyan Wu
Anticancer Effects of Gleditsia sinensis Extract in Rats Transplanted With Hepatocellular Carcinoma Cells – 889 Yue Cai, Chizhi Zhang, Lei Zhan, Liangbin Cheng, Dingbo Lu, Xiaodong Wang, Hanlin Xu, Shuxue Wang, Deng Wu, and Lianguo Ruan
Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib – 901 Yueming He, Wang Sheng, Weiguo Hu, Jing Lin, Junjun Liu, Bing Yu, Xinru Mao, Lu Zhang, Jin Huang, and GuangsuoWang
miR-148-3p Inhibits Growth of Glioblastoma Targeting DNA Methyltransferase-1 (DNMT1) – 911 Yongtao Li, Fanyu Chen, Jiancheng Chu, Chao Wu, Yuan Li, Heng Li, and Hongxin Ma
PPARβ/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by Regulating miR-206 – 923 Linglan Gu, Yi Shi, Weimin Xu, and Yangyang Ji
NET1 Enhances Proliferation and Chemoresistance in Acute Lymphoblastic Leukemia Cells – 935 Hongbo Sun, Zhifu Zhang, Wei Luo, Junmin Liu, Ye Lou, and Shengmei Xia
Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts – 945 Yosuke Mitsui, Nahoko Tomonobu, Masami Watanabe, Rie Kinoshita, I Wayan Sumardika, Chen Youyi, Hitoshi Murata, Ken-ichi Yamamoto, Takuya Sadahira, Acosta Gonzalez Herik Rodrigo, Hitoshi Takamatsu, Kota Araki, Akira Yamauchi, Masahiro Yamamura, Hideyo Fujiwara, Yusuke Inoue, Junichiro Futami, Ken Saito, Hidekazu Iioka, Eisaku Kondo, Masahiro Nishibori, Shinichi Toyooka, Yasuhiko Yamamoto, Yasutomo Nasu, and Masakiyo Sakaguchi
FCY-302, a Novel Small Molecule, Induces Apoptosis in Leukemia and Myeloma Cells by Attenuating Key Antioxidant and Mitochondrial Enzymes – 957 Prasanna Rajagopalan, Abdulrahim Hakami, Mohammed Ragab, and Ashraf Elbessoumy
The Role of Toll-Like Receptors in Oncotherapy – 965 Caiqi Liu, Ci Han, and Jinfeng Liu
Back issues of this journal are available online. Order Here
Oncology Research is indexed in:
Web of Science Coverage: SCIENCE CITATION INDEX EXPANDED BIOLOGICAL ABSTRACTS BIOSIS FULL COVERAGE SHARED BIOSIS PREVIEWS CC/LIFE SCIENCES CURRENT CONTENTS PROCESSING CODE DERWENT DRUG FILE ESSENTIAL SCIENCE INDICATORS JOURNAL CITATION REPORTS SCIENCE PROUS RESEARCH ALERT
CABI HEAD OFFICE CHEMICAL ABSTRACTING SERVICES EBSCO DISCOVERY SERVICES-EDS GOOGLE ANALYTICS OCLC PRIMO CENTRAL PROQUEST SCOPUS SOCIEDAD LIBEROAMERICANA DE THOMSON REUTERS WORLDCAT DISCOVERY SERVICES
Disclaimer: Although every effort is made by the publisher and editorial board to see that no inaccurate or misleading data, opinion, or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the sole responsibility of the contributor or advertiser concerned. Accordingly, the publisher, editors, editorial board, and their respective employees, officers, and agents accept no responsibility or liability whatsoever for the consequences of any such inaccurate or misleading data, opinions, or statements.
Copyright Notice: It is a condition of publication that manuscripts submitted to this Journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for the articles is transferred to the publisher, if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform, or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording, or otherwise, without permission in writing from the copyright holder.
Photocopying information for users in the USA: The Item Fee Code for this publication indicates that authorization to photocopy item for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $90.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923. The copyright owner’s consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt, please contact Cognizant Communication Corporation. The Item Fee Code for this publication is 0965-0407/10 $90.00
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics is indexed and abstracted in: Current Contents/Life Sciences, Science Search, Science Citation Index, Research Alert, MEDLARS, MEDLINE, Index Medicus, BIOSIS, SIIC (Sociedad Iberoamericana de Información Cientifica) Database, and CABS (Current Awareness in Biological Sciences).
Robert N. Miranda, Publisher/Chairman Lori H. Miranda, President/COO
P.O. Box 37, 18 Peekskill Hollow Road Putnam Valley, NY 10579, USA